Comparative therapeutic efficacy study of Lactobacilli probiotics and citalopram in treatment of acute stress-induced depression in lab murine models

Q1 Medicine

Human Microbiome Journal Pub Date : 2018-12-01 DOI:10.1016/j.humic.2018.08.001

Abdalla M. Abdrabou, Enass Y. Osman, Osama A. Aboubakr

{"title":"Comparative therapeutic efficacy study of Lactobacilli probiotics and citalopram in treatment of acute stress-induced depression in lab murine models","authors":"Abdalla M. Abdrabou, Enass Y. Osman, Osama A. Aboubakr","doi":"10.1016/j.humic.2018.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>A relationship between Microbiome and its effect on depression has been suspected in earlier studies. Here we examined whether the addition of Lactobacillus probiotics which flourishes the gut-microbiota will have a beneficial adjuvant therapeutic effect on treatment of depression or even considering it as a main treatment line in the future for treatment of depression or anxiety like behavior after further studies. Mice receiving probiotics in their diet exhibited mostly similar anxiolytic and anti-depressive effects of the mice that received SSRI anti-depressant citalopram and displayed enhanced outcomes which were shown in the Tail Suspension test – which is considered a high output tool in assessing anti-depression medications –, Super oxidase dismutase concentration in the brain tissue and HPLC analysis of Kynurenine biomarker in the brain. Taken together these data support the link between healthy gut microbiome and its effect on depression-like behavior and suggest that probiotics may even have a similar therapeutic effect of anti- depressants in treatment of depression.</p></div>","PeriodicalId":37790,"journal":{"name":"Human Microbiome Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.humic.2018.08.001","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Microbiome Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452231718300186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 11

Abstract

A relationship between Microbiome and its effect on depression has been suspected in earlier studies. Here we examined whether the addition of Lactobacillus probiotics which flourishes the gut-microbiota will have a beneficial adjuvant therapeutic effect on treatment of depression or even considering it as a main treatment line in the future for treatment of depression or anxiety like behavior after further studies. Mice receiving probiotics in their diet exhibited mostly similar anxiolytic and anti-depressive effects of the mice that received SSRI anti-depressant citalopram and displayed enhanced outcomes which were shown in the Tail Suspension test – which is considered a high output tool in assessing anti-depression medications –, Super oxidase dismutase concentration in the brain tissue and HPLC analysis of Kynurenine biomarker in the brain. Taken together these data support the link between healthy gut microbiome and its effect on depression-like behavior and suggest that probiotics may even have a similar therapeutic effect of anti- depressants in treatment of depression.

查看原文本刊更多论文

乳酸杆菌益生菌与西酞普兰治疗小鼠急性应激性抑郁症的疗效比较研究

在早期的研究中，人们怀疑微生物组与其对抑郁症的影响之间存在关系。在这里，我们进一步研究了益生菌乳杆菌的添加是否会对治疗抑郁症有有益的辅助治疗作用，甚至在未来的研究中考虑将其作为治疗抑郁或焦虑样行为的主要治疗方法。在饮食中服用益生菌的小鼠表现出与服用SSRI抗抑郁药西酞普兰的小鼠相似的抗焦虑和抗抑郁效果，并在Tail Suspension测试(被认为是评估抗抑郁药物的高输出工具)、脑组织超氧化酶歧化酶浓度和大脑中犬尿氨酸生物标志物的HPLC分析中显示出增强的结果。综上所述，这些数据支持健康的肠道微生物群与其对抑郁样行为的影响之间的联系，并表明益生菌在治疗抑郁症方面甚至可能具有与抗抑郁药相似的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Microbiome Journal Medicine-Infectious Diseases

自引率

0.00%

发文量

期刊介绍： The innumerable microbes living in and on our bodies are known to affect human wellbeing, but our knowledge of their role is still at the very early stages of understanding. Human Microbiome is a new open access journal dedicated to research on the impact of the microbiome on human health and disease. The journal will publish original research, reviews, comments, human microbe descriptions and genome, and letters. Topics covered will include: the repertoire of human-associated microbes, therapeutic intervention, pathophysiology, experimental models, physiological, geographical, and pathological changes, and technical reports; genomic, metabolomic, transcriptomic, and culturomic approaches are welcome.